MissionIR Articles
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) CEO to Participate at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, will be part of the upcoming H.C. Wainwright Psychedelics in Psychiatry and Beyond conference. The all-virtual conference is slated for June 17,…
-
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Kernel Flow, Ketamine Feasibility Study
Feasibility study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics Cybin, Kernel working together to leverage proprietary Kernel Flow device for psychedelic-based studies and clinical trials Ketamine is a dissociative injected anesthetic…
-
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files International Patent to Protect Potential Patient Coverage in 153 Countries
Cybin submits first-ever Patent Cooperation Treaty (“PCT”) filing By filing a single PCT application, the company simultaneously seeks protection for its proprietary drug treatments in a large number of countries Cybin filed the PCT application to…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Develops New Treatment Model, Announces Co-Sponsorship of First-Ever Trial to Treat Frontline Clinicians
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has developed EMBARK, a transdiagnostic psychotherapy model, and will be co-sponsoring an upcoming trial designed for frontline clinicians experiencing COVID-related distress. Cybin…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Participate at Upcoming LD Micro Invitational XI
Cybin (NEO: CYBN) (OTCQB: CLXPF) CEO Doug Drysdale will be participating at the 2021 LD Micro Invitational XI. The invitational will be held Thursday, June 10. As part of his participation, Drysdale will be presenting…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Pioneering Study Designed to Expand Understanding of Psychedelic Pharmacotherapy
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel’s feasibility study of its Kernel Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics.…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces PCT Filing, Bringing Potential to Obtain Patent Coverage in 153 Countries
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed an international patent application that further strengthens its psychedelic derivative drug development candidates across 153 global…
-
Cybin Inc. (NEO: CYBN) Files Patent Designed to Bolster IP Psychedelic Molecule, Delivery Mechanism Portfolio
Company files 12th patent to strengthen proprietary IP program Cybin believes treatments can decrease costs, increase access to important therapeutics Patent provides wide range of benefits in Cybin’s four drug candidate program Cybin (NEO: CYBN)…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Expands Team to Add Deep Clinical, Commercial and Regulatory Expertise
Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently appointed Alexander Belser as its chief clinical officer and Aaron Bartlone to serve as chief operating…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Strengthens IP Portfolio with 12th Patent Filing
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has filed a provisional patent application in support of its ongoing drug candidate programs. The patent is the 12th patent filed by…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Secures IRB Approval to Commence Study of Psilocybin Formulation in Treatment of Major Depressive Disorder
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the Institutional Review Board (“IRB”) at the University of the West Indies Hospital in Jamaica has granted approval to…
-
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Maintains Buy Rating in Recent Equity Update
April analyst reports all point to a bright future for Cybin “CYBN is a true multi-molecule company that’s not being reflected in its valuation,” reports Stifel “With a relatively small 5% penetration, Cybin could achieve…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Collaborates to Potentially Develop New Therapy for Treatment-Resistant Psychiatric Disorders
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently acquired Adelia Therapeutics, thereby adding CYB003 to its pipeline. It subsequently made an equally important move when…
-
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Looks to New Senior Management with Expertise in Development, Clinical Capabilities
Company committed to building presence in U.S. and Europe to advance mission of improving mental health care New appointments will strengthen Cybin’s development and clinical operations globally, solidify position within the industry New leaders bring…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) CEO to Present at Global Small Cap Conference
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced that CEO Doug Drysdale will be presenting at the upcoming Benzinga Global Small Cap Conference. The conference, slated for Thursday, May…
-
Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Signs Drug-Development Agreement, One Step Closer to Effective Psychiatric Disorder Treatment
Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disorders Cybin looking to identify fast-acting, shorter-duration formulations of CYB003 Delivering CYB003 through Catalent ODT could provide significant benefits Cybin…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Eyes Rapid Progress to Clinical Studies for Psychedelic Drug Candidates
Cybin (NEO: CYBN) (OTCQB: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has completed key in-vitro and in-vivo research studies. The company recently announced completion of its 20th pre-clinical…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces AUD Disorder Indication for Psychedelic Molecule CYB003
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has selected alcohol use disorder (“AUD”) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003. In the announcement, the…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces Data Providing Strong Support to Advance Drug Development Candidates
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that it has successfully demonstrated proof of concept for its deuterated tryptamine programs, CYB003 and CYB004, for the treatment of…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Establishes Clinical Advisory Board, to Present at Bloom Burton & Co. Health Care Investor Conference
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced the formation of its clinical advisory board. Additions to the board include Maurizio Fava, MD, psychiatrist-in-chief in the Department of…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial